Status:
COMPLETED
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)
Lead Sponsor:
North Texas Veterans Healthcare System
Conditions:
Myocardial Infarction
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus reg...
Detailed Description
SCORE is a multicenter, prospective randomized study of post-percutaneous coronary intervention (PCI) patients with an uneventful 1 year post-PCI course on dual anti-platelet therapy (DAPT) with clopi...
Eligibility Criteria
Inclusion
- Post-PCI patients receiving at least 1 DES
- Completed 9-15 months follow-up free of MI, repeat revascularization
- Able to provide informed consent
- Have continued dual anti-platelet therapy with aspirin and clopidogrel for 1 year post-PCI
Exclusion
- Patients allergic to aspirin
- Patients with aspirin resistance
- Patients with allergy to clopidogrel
- Patients on concomitant warfarin therapy
- History of bleeding diathesis, coagulopathy, and/or platelet count \< 100,000 cubic mm
- Patients with a life expectancy less than 1 year due to active cancers (except basal cell carcinoma)
- Pregnancy
Key Trial Info
Start Date :
September 11 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2014
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT00781573
Start Date
September 11 2008
End Date
March 3 2014
Last Update
September 13 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dallas Veterans Hospital
Dallas, Texas, United States, 75216
2
The Onassis cardiac Surgery Centre
Athens, Greece
3
Escorts Health Institute & Research Centre Ltd
New Delhi, India